20 results
424B3
PRTG
Portage Biotech Inc
28 Feb 24
Prospectus supplement
5:19pm
. Biodegradable PLGA-nanoparticles function as a delivery platform for immunomodulators and tumor antigens to induce a specific anti-tumor immune
6-K
EX-99.2
PRTG
Portage Biotech Inc
28 Feb 24
Current report (foreign)
5:17pm
formulation of PORT-2 (IMM60) combined with a NY-ESO-1 peptide vaccine. Biodegradable PLGA-nanoparticles function as a delivery platform for immunomodulators
424B3
PRTG
Portage Biotech Inc
28 Nov 23
Prospectus supplement
4:03pm
formulation of PORT-2 (IMM60) combined with a NY-ESO-1 peptide vaccine. Biodegradable PLGA-nanoparticles function as a delivery platform
6-K
EX-99.2
PRTG
Portage Biotech Inc
28 Nov 23
Current report (foreign)
4:01pm
. Biodegradable PLGA-nanoparticles function as a delivery platform for immunomodulators and tumor antigens to induce a specific anti-tumor immune
424B5
PRTG
Portage Biotech Inc
2 Oct 23
Prospectus supplement for primary offering
6:01pm
and institution ethics approval. The combination product has the ability to prime and boost an anti-tumor immune response.
Biodegradable PLGA
6-K
EX-99.2
xhsytq0olgm5e
29 Aug 23
Current report (foreign)
4:01pm
6-K
EX-99.2
gct2fpc
29 Nov 22
Current report (foreign)
4:58pm
6-K
EX-99.2
w8jdr srvhofz
29 Aug 22
Current report (foreign)
4:00pm
6-K
EX-99.2
741 ea5h7zu6tr
25 Feb 22
Current report (foreign)
5:29pm
6-K
EX-99.2
91xulv3t2pqkzi17ti
23 Nov 21
Current report (foreign)
4:30pm
6-K
EX-99.2
6qff0b690q
30 Aug 21
Current report (foreign)
5:21pm
SUPPL
awxxjr49t46
24 Jun 21
Supplemental materials (foreign)
5:27pm
SUPPL
dgy 53suzsbot7ce51n
23 Jun 21
Supplemental materials (foreign)
4:01pm
424B2
i917 aj97e7jj7m1
8 Mar 21
Prospectus for primary offering
5:00pm
6-K
EX-99.2
uymfd6fz423q3y
1 Mar 21
Condensed Consolidated Interim Financial Statements
4:23pm
F-3
r6vdnwx 20
24 Feb 21
Shelf registration (foreign)
5:22pm
- Prev
- 1
- Next